Tigecycline MRA InChi: InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23

InChi: InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23

is an alkaloid isolated from Nocardiopisis bacteria

orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2

2ClH/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17

Tigecycline MRA InChi: InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23Tigecycline is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U. S. Food and Drug Administration (FDA) fast track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo Lactamase multidrug resistant Enterobacteriaceae